Population-wide Research for HBV-related Liver Diseases in Maoming City

Not yet recruitingOBSERVATIONAL
Enrollment

3,700,000

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

August 31, 2025

Conditions
HBV InfectionChronic Hepatitis BCirrhosisHCC
Interventions
OTHER

Rapid tests for HBsAg

"Participants in the screening group will firstly receive the HBsAg screening using a finger blood test.~The laboratory examination includes blood routine test (white blood cell count \[WBC\], red blood cell count \[RBC\], hemoglobin \[HGB\], platelet count \[PLT\]), liver function (total bilirubin \[TBIL\], albumin \[ALB\], alanine aminotransferase \[ALT\]), HBV serologic markers, alpha-fetoprotein(AFP) , abnormal Prothrombin II (PIVKA II) and HBV-DNA.~The imaging examination includes liver ultrasound, abdominal CT, or MRI. HBsAg-positive participants also undergo liver ultrasound examination. If suspicious liver nodules or elevated AFP levels are detected, further refinement through abdominal CT or MRI is recommended."

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT06184347 - Population-wide Research for HBV-related Liver Diseases in Maoming City | Biotech Hunter | Biotech Hunter